Quantcast
Last updated on April 17, 2014 at 15:58 EDT

Latest Vanda Stories

2014-01-23 16:25:34

Conference Call and Webcast to Follow WASHINGTON, Jan. 23, 2014 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders, today announced it will release results for the fourth quarter of 2013 on Thursday, February 13, 2014, before the market opens. The Company will host a conference call at 10:00 AM ET on Thursday, February 13,...

2013-10-21 20:22:09

Conference Call and Webcast to Follow WASHINGTON, Oct. 21, 2013 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders, today announced it will release results for the third quarter of 2013 on Thursday, November 7, 2013, before the market opens. The Company will host a conference call at 10:00 AM ET on Thursday, November 7, 2013,...

2013-08-06 16:27:53

NEW YORK, Aug. 6, 2013 /PRNewswire/ -- Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the District of Columbia on behalf of investors who purchased Vanda Pharmaceuticals, Inc. ("Vanda" or the "Company") (NasdaqGM: VNDA) stock between December 18, 2012 and June 18, 2013. (Logo: http://photos.prnewswire.com/prnh/20120409/MM84375LOGO ) For more information, click here: http://zlk.9nl.com/vanda-pharmaceuticals-vnda/....

2013-07-29 20:21:14

Conference Call and Webcast to Follow WASHINGTON, July 29, 2013 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders, today announced it will release results for the second quarter of 2013 on Wednesday, July 31, 2013, before the market opens. The Company will host a conference call at 10:00 AM ET on Wednesday, July 31, 2013,...

2013-07-03 20:20:36

SAN DIEGO and WASHINGTON, July 3, 2013 /PRNewswire/ -- Shareholder rights attorneys at Robbins Arroyo LLP announce that a shareholder of Vanda Pharmaceuticals, Inc. (NasdaqGM: VNDA) securities has filed a complaint in the U.S. District Court for the District of Columbia against the company and certain of its officers and directors. The complaint alleges that defendants violated the Securities Exchange Act of 1934 between December 18, 2012 and June 18, 2013 (the "Class Period")....

2013-05-24 00:20:29

WASHINGTON, May 23, 2013 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced that the company has been named the 2013 Life Science Firm of the Year by the Tech Council of Maryland (TCM). Vanda was honored at the TCM's 25(th) Annual Tech Awards Celebration held in Bethesda, Maryland. The Tech Awards Celebration recognizes the leaders and innovators in the technology and life science communities in Maryland and the surrounding regions. "We are deeply honored to...

2013-05-09 08:29:55

WASHINGTON, May 9, 2013 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders, today announced financial and operational results for the first quarter ended March 31, 2013. Key Highlights: On March 25, 2013, Vanda announced that it held a successful Pre-New Drug Application meeting with the U.S. Food and Drug Administration (FDA). The...

2013-04-17 20:21:27

WASHINGTON, April 17, 2013 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), announced today that it has named Paolo Baroldi, M.D., Ph.D. as its Senior Vice President and Chief Medical Officer. Dr. Baroldi has over 30 years of clinical development experience in many therapeutic areas, including neurology and psychiatry. He has been working in the role of acting Chief Medical Officer with Vanda since October 1, 2012. "We welcome Paolo to Vanda and look forward to his...

2013-03-25 08:26:21

WASHINGTON, March 25, 2013 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced that the company held a pre-NDA meeting with the Division of Neurology Products of the U.S. Food and Drug Administration (FDA) to discuss the regulatory path for filing a New Drug Application (NDA) for tasimelteon, a circadian regulator, for the treatment of Non-24-Hour Disorder (Non-24). Non-24 is a serious, rare circadian rhythm disorder that affects a majority of totally blind...

2013-03-14 16:28:05

WASHINGTON, March 14, 2013 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) announced today that it has withdrawn its Marketing Authorization Application (MAA) submitted to the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) for Fanaptum(TM) (oral iloperidone tablets) for the treatment of adult patients with schizophrenia. This withdrawal is based on a request by the CHMP/Rapporteur/Co-rapporteur for Vanda to submit the results from an...